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Abstract  
Crisponi/Cold-induced sweating syndrome (CS/CISS) is a rare autosomal recessive disorder characterized 
by a complex phenotype (hyperthermia and feeding difficulties in the neonatal period, followed by 
scoliosis and paradoxical sweating induced by cold since early childhood) and a high neonatal lethality. 
CS/CISS is a genetically heterogeneous disorder caused by mutations in CRLF1 (CS/CISS1), in CLCF1 
(CS/CISS2) and in KLHL7 (CS/CISS-like). Here, a whole exome sequencing approach in individuals 
with CS/CISS-like phenotype with unknown molecular defect revealed unpredicted alternative diagnoses. 
This approach identified putative pathogenic variations in NALCN, MAGEL2 and SCN2A. They were 
already found implicated in the pathogenesis of other syndromes, respectively the congenital contractures 
of the limbs and face, hypotonia, and developmental delay syndrome (CLIFAHDD), the Schaaf-Yang 
syndrome (SHFYNG), and the early infantile epileptic encephalopathy-11 syndrome (EIEE11). These 
results suggest a high neonatal phenotypic overlap among these disorders and will be very helpful for 
clinicians. Genetic analysis of these genes should be considered for those cases with a suspected CS/CISS 
during neonatal period who were tested as mutation negative in the known CS/CISS genes, since an 
expedited and corrected diagnosis can improve patient management and can provide a specific clinical 
follow up.  
Keywords: Crisponi/Cold induced sweating syndrome; CRLF1; MAGEL2; NALCN; SCN2A; whole 
exome sequencing. 
 
 Introduction 
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Crisponi syndrome (CS), the infantile presentation of cold-induced sweating syndrome (CISS), is 
characterized by dysmorphic features (distinctive facies, lower facial weakness, flexion deformity at the 
elbows, camptodactyly with fisted hands, misshapen feet, and overriding toes), poor suck reflex, severely 
impaired swallowing, and temperature spikes associated with an increased risk for seizures and sudden 
death.  
CISS can present to the clinician from age 3 years onward as cold-induced sweating. Starting the first 
decade of life, children with CS/CISS develop profuse sweating of the face, arms and chest with ambient 
temperatures below 18°C to 22°C, and with other stimuli including apprehension or ingestion of sweets. 
Affected individuals sweat very little in hot environments and may feel overheated. In the second decade, 
progressive thoracolumbar kyphoscoliosis requiring intervention is common.1 
The diagnosis of CS/CISS syndrome (MIM#272430) is established by clinical findings and by 
identification of pathogenic variants in CRLF1 or CLCF1. So far more than 95% of cases are caused by 
mutations in CRLF1 (CISS1), while the remaining by mutations in CLCF1 (CISS2).1 Alterations in 
CRLF1 and CLCF1 can be found in more than 60% of individuals with clinical diagnosis of CS/CISS.2-4 
Therefore, a subset of CS/CISS cases (about 40%) remains yet genetically unexplained. In 2016, KLHL7 
has been found mutated in five individuals with a CS/CISS-like phenotype associated to retinitis 
pigmentosa.5  
We report here the results from a trio-based whole exome sequencing (WES) study in five unsolved 
individuals with an initial clinical diagnosis of CS/CISS. The aim of this study was to detect novel 
variants, and novel CS/CISS-like genes. We provide further evidence of locus heterogeneity within the 
CS/CISS-like phenotype spectrum and highlight overlaps with different syndromes requiring careful 
differential diagnoses. 
 
Methods: case presentations 
Five individuals with the initial diagnosis of CS/CISS but negative for mutations in CRLF1 and CLCF1 
were clinically assessed by the respective clinical geneticists and selected for WES analysis. Clinical 
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findings of these cases are listed in Table 1. Our inclusion criteria comprised features related to the 
neonatal phenotype and especially to the four main typical CS criteria: hyperthermia in the first months of 
life, feeding difficulties, contraction of oropharyngeal muscles and camptodactyly.  
We assigned the five cases to rank 1 (very likely) and 2 (questionable) based on their phenotype similarity 
to CS/CISS. Rank 1 individuals (CS_239 and CS_306) presented in the neonatal period the four main 
typical CS criteria, while rank 2 (CS_125, CS_141 and CS_207) individuals fulfilled two or three of them 
(See clinical details and WES analysis, Supporting Information) 
 
Molecular results 
Here we identified two de novo missense variants in NALCN NM_052867.3: c.1800C>A: p.(Asp600Glu) 
and c.1571G>A: p.(Ser524Asn) in two unrelated CS patients (Family A and C). These novel variants, 
predicted as pathogenic by LRT, MutationTaster, Polyphen2 and FATHMM, occurred at highly 
conserved amino acids within NALCN from different organisms, even those very distinct from 
vertebrates. NALCN forms a voltage-independent, nonselective, non-inactivating cation channel 
permeable to Na+, K+, and Ca (2+). It is responsible for the neuronal background sodium leak 
conductance.11 Functional testing of some human variants in C. elegans demonstrated that CLIFAHDD 
can be caused by dominant loss or gain of function mutations in ion channel function. In 2016, Bend et 
al.12 conducted functional studies on C. elegans NCA-1 mutants carrying the p.(Asp647Glu) mutation, 
which is the orthologous position of p.(Asp600Glu) in human NALCN. They described this de novo 
variant as a gain of function, which gives very severe effects. In animal model, this mutation displays 
dramatically reduced locomotion, small body size and curly posture, consistent with neuronal 
dysfunction. 
In family B and E, we identified two MAGEL2 mutations of paternal origin: a de novo NM_019066.4: 
c.2056_2066del: p.(Trp686Alafs*23), already reported, and an insertion c.1996dupC: 
p.(Gln666Profs*47): rs770374710 which represents a mutational hotspot.13 
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In family D, we identified a de novo mutation in the SCN2A gene, NM_001040143.1: c.2567G>A: 
p.(Arg856Gln): rs797045942, which has been previously reported as associated to Ohthara syndrome.18 
This substitution results in the conversion of an arginine to glutamine. This arginine is highly conserved 
within SCN2A from different organisms, even those very distinct from vertebrates. It is predicted to be 
pathogenic by five popular algorithms, SIFT, Polyphen2, LRT, Mutation Assessor, and FATHMM. 
Table 2 provides a summary of the patients’ features and of the ACMG criteria satisfying the pathogenic 
nature of the identified variants in NALCN, MAGEL2 and SCN2A.  
 
Discussion 
A trio-based WES in five individuals with an initial clinical diagnosis of CS/CISS disclosed alternative 
diagnoses not originally considered in the differential diagnosis in these children, and emphasizes the 
wide clinical spectrum overlap among different syndromes (Figure 1). These diagnoses include the 
CLIFAHDD,6 the Schaaf-Yang (SHFYNG),7 and the early infantile epileptic encephalopathy type 11 
(EIEE11)8 syndromes caused by heterozygous mutations respectively in NALCN, MAGEL2 or SCN2A.  
An accurate revaluation of the clinical phenotype of each case reported so far, based on what found by 
WES, helped us to reassess it within the previous unpredicted diagnosis. 
CLIFAHDD syndrome – NALCN gene 
CLIFAHDD (MIM#616266) is an autosomal dominant disorder firstly described in 2015 by Chong et 
al.,6 in five individuals initially diagnosed as having Freeman-Sheldon syndrome, or distal arthrogryposis 
type 2A (DA2A). Clinical features of CLIFAHDD are congenital contractures of the limbs and face, 
resulting in characteristic facial features, hypotonia, neonatal respiratory distress and variable degrees of 
developmental delay. Interestingly, CS/CISS was considered in the differential diagnosis for CLIFAHDD 
syndrome in two reported cases, of whom one actually had a heterozygous mutation in NALCN.6,9  In the 
past, DA2A has been considered in the differential diagnosis of CS/CISS, particularly for the intermittent 
facial muscle contraction, the puckering of the lips of young children and for the camptodactyly although 
the clinical course is completely different.10  
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SHFYNG syndrome - MAGEL2 gene 
SHFYNG syndrome (MIM#615547) is an autosomal dominant multisystem disorder characterized by 
delayed psychomotor development, intellectual disability, neonatal hypotonia with poor sucking, feeding 
difficulties in infancy and behavioral abnormalities. Additional features include contractures and variable 
dysmorphic facial features. It is caused by mutations in MAGEL2, and individuals are affected only if the 
mutation occurs on the paternal allele, since MAGEL2 is an imprinted, maternally silenced, gene located 
at 15q11-13, within the Prader-Willi region.7 
A de novo nonsense mutation in MAGEL2 was identified in one individual presenting with severe 
congenital contractures initially diagnosed as having Opitz-C syndrome (OTCS; MIM#211750),14 
indicating that there is an overlap between OTCS and SHFYNG syndromes. In addition, MAGEL2 
mutations were reported in individuals initially diagnosed as having Chitayat-Hall syndrome 
(MIM#208080) leading to the conclusion that Chitayat-Hall and SHFYNG syndromes are likely the same 
disorder.15 MAGEL2 is highly expressed in the hypothalamus and it is part of a multi-subunit protein 
complex consisting of MAGEL2, the TRIM27 E3 ubiquitin ligase, and the USP7 deubiquitinating 
enzyme.  
EIEE11 - SCN2A gene 
Infantile/childhood onset epileptic encephalopathies or early infantile epileptic encephalopathies (EIEE) 
represent a collection of serious seizure disorders. Particularly, early infantile epileptic encephalopathy-11 
(EIEE11; MIM#613721) is caused by heterozygous mutations in the SCN2A gene and is typically 
characterized by severe, very early onset intractable seizures with subsequent developmental delay 
occasionally including autistic type symptoms. Variants in SCN2A are associated with a wide range of 
phenotypic heterogeneity (i.e. Ohtahara syndrome, epilepsy of infancy with migrating focal seizures, 
infantile spasms, West syndrome or unclassified severe epilepsy phenotypes and ASD/ID, characterized 
by global developmental delay, particularly of social and language milestones) and the mechanisms 
underlying this are poorly understood.16   
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The SCN2A gene encodes the voltage-gated sodium channel Nav1.2, one of the major neuronal sodium 
channels that play a role in the initiation and conduction of action potentials, chiefly in nerve and muscle. 
 
Conclusions 
In summary, heterozygous mutations in NALCN, MAGEL2 and SCN2A can result in a CS/CISS-
overlapping phenotype, which seems to be most similar in the neonatal period. Although CS/CISS, 
CLIFAHDD, SHFYNG and EIEE11 syndromes show overlapping features such as feeding problems in 
infancy, contractures and temperature instability, they must be considered as distinct entities. These 
observations suggest that similar pathophysiological mechanisms may lead to such clinically overlapping 
phenotypes.  
Based on the considerable phenotypic overlap between CS/CISS and other syndromes described in this 
article, the clinical geneticist should employ the current clinical diagnostic criteria for CS/CISS with 
caution, especially in the neonatal period. Adequate counseling should only be possible after the 
diagnosis has been confirmed by molecular genetic testing. Therefore, sequencing analysis of these genes 
has to be considered for those cases with a suspected CS/CISS during neonatal period who were tested as 
mutation negative in the known genes, since an expedited and corrected diagnosis can improve patient 
management and can provide a specific clinical follow up.  
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Figure legend 
Figure 1: CS/CISS-like families analyzed by WES. 
(A) Family pedigrees of individuals with mutations found by WES. Symbols and colors are defined as 
follows: square, male; circle, female; white, unaffected; dot, unaffected carrier; black, affected. Mutation 
status is indicated beneath symbols for each subject. +/- heterozygous carriers. (B) Sanger sequencing of 
the five mutations found by WES. Panels shows heterozygous status for CS_125 [NALCN c.1800C>A: 
p.(Asp600Glu)], CS_141 [MAGEL2 c.2056_2066del: p.(Trp686Alafs*23)], CS_207 [NALCN 
c.1571G>A: p.(Ser524Asn)], CS_239 [SCN2A c.2567G>A: p.(Arg856Gln)] and CS_306 [MAGEL2 
c.1996dupC: p.(Gln666Profs*47)]. (C) Photographs of all the cases analyzed at the neonatal age. Written 
informed consent for publication of their clinical images was obtained from their parents. 
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Category Feature CS/CISS SHFYNG CLIFAHDD EIEE11 Family A Family B Family C Family D Family E 
General Autism spectrum disorder  +        
 Cognitive delay   +   +   + 
 Cold induced sweating > 3years +    Increased sweating without fever   Cold induced sweating < 3 years Profuse sweating 
 Dehydration +       Low serum sodium Central diabetes insipidous during 
neonatal period 
 Decreased fetal movements  +   +   +  
 Developmental delay  +   + + +  + 
 Excessive weight gain  +        
 Hypotonia (at time of exam)  +      + + 
 Hyperphagia  +        
 Hyperthermia +       + + 
 Intellectual Disability  +   + + +  + 
 Neonatal hypotonia, poor suck + +   GJ tube feeding, hypotonia at rest, 
hypertonia when handled or agitated 
NG tube feeding, hypotonia at rest and 
hypertonia when handled or agitated 
NG tube feeding NG tube feeding, reduced movements 
and startling movements when 
handled 
NG tube feeding, hypotonia at rest, 
hypertonia when handled or agitated 
 Short stature  +    +    
 Temperature instability + +      + + 
Gastrointestinal Chronic constipation  +    +   + 
 Feeding difficulties + +   + + Mostly nasogastric  feeding + + 
 Gastroesophageal reflux + + +  +  +   
 Swallowing difficulties +    + + + + + 
CNS EEG shows abundant slow waves and fast spike activity    +      
 EEG shows suppression with ictal burst activities    +    +  
 Febrile seizures +   +      
 Seizures, tonic-clonic    + +   +  
 Spastic quadriplegia    +      
 Status epilepticus    +    Severe encephalopahy  
Craniofacial Anteverted nasal tip +  +  +  +  + 
 Broad nasal bridge   +  + + +  - 
 Chubby cheeks +  +  + + + ? + 
 Deep nasolabial folds   +  + + +   
 Depressed nasal bridge +    + + + +  
 Downslanting palpebral fissures   +    + Upslanting palpebral fissures  
 H-shaped dimple chin   +    + +  
 High arcade palate +    +    + 
 Full cheeks +  +  + + +  + 
 Large nares +  +  +     
 Long philtrum +  +  + + +   
 Micrognathia +  +  +  + + + 
 Pursed lips +  +  +  Small mouth +  
 Short columnella   +  + +    
Ophtalmologic Esotropia  + +       
 Strabismus  +       + 
Musculoskeletal Adducted thumb +  +  +  +   
 Calcaneovalgus deformity   +  +  +   
 Camptodactyly + + +  + + + + + 
 Clubfoot +  +  +  + +  
 Contractures of finger joints + +   + + + + + 
 Contraction of oropharyngeal muscles +    +  + + + 
 Elbow contractures +  +  + +  + + 
 Foot anomalies +  +  +  Bilateral talipes Unilateral clubfoot, overriding toes  
 Hip contractures   +      + 
 Joint contractures +    + + Clenched hands, difficult to fully 
extend knees 
+ + 
 Knee contractures   +  + + + + + 
 Muscle contractions, episodic +    + + Abnormal movement Startling movements when touched  
 Scoliosis + + +   Kyphoscoliosis    
 Short neck   +  +  +   
 Small hands  +   + +    
 Small feet  +   + +    
 Ulnar deviation   +   + + + + 
Behaviour Behavioral abnormaliities (impulsivity, compulsivity, 
stubbornness) 
 +        
 Skin picking, automutilation  +        
Genitourinary Hypogonadism  +    Hypoplastic scrotum    
Cardiopulmonary Cyanosis +    +  + Sectio, meconium, respiratory 
treatment and CPAP, APGAR  3-3-7 
 
 Dyspnea/apneic spells +     + +   
 Respiratory distress +    +  +   
 Sleep apnea  +   + + +  + 
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le  Table 1. Phenotypic comparison among Crisponi/CISS-like individuals harboring pathogenic or likely pathogenic variants detected by WES. Clinical symptoms specific for a given syndrome as described at clinical synopsis available at the Online Mendelian Inheritance in Man website are coloured accordingly (CS/CISS, 
blue; SHFYNG, greeŶ; CLIFAHDD, piŶk; EIE11, yelloǁ). ͞+͟ iŶ faŵily ĐoluŵŶs deŶotes that the patieŶt presented the giǀeŶ feature, aŶd ͞ďlaŶk͞ deŶotes that the 
patient did not presented the given feature or the feature could not be evaluated due to the early age. GJ, gastro-jejunal; NG, nasogastric; CNS, Central nervous 
system; EEG, electroencephalogram. 
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Sex Female Male Male Female Male 
Year of molecular diagnosis 2017 2017 2017 2017 2017 
Nationality Canadian Spanish British Swedish Spanish 
Year of birth 2008 2008 2010 2012 2014 
Age of death 3-1/2 months  10 months 3-1/2 months  
Origin Scottish/Northern 
European 
Spanish Wales Caucasian  Romanian 
Consanguinity - - - - - 
Gene NALCN MAGEL2  NALCN  SCN2A MAGEL2 
HGVS variant nomenclature NM_052867.3: 
c.1800C>A: 
p.(Asp600Glu) 
NM_019066.4: 
c.2056_2066del: 
p.(Trp686Alafs*23) 
NM_052867.3: 
c.1571G>A: 
p.(Ser524Asn) 
NM_001040143.1: 
c.2567G>A: 
p.(Arg856Gln) 
NM_019066.4: 
c.1996dupC: 
p.(Gln666Profs*47) 
Mutation type Missense Frameshift  Missense Missense Frameshift 
Zygosity Het (de novo) Het (de novo) Het (de novo) Het (de novo) Het (paternal) 
ACMG classification Pathogenic (ii) Pathogenic (i) Likely pathogenic (ii) Likely pathogenic (ii) Pathogenic (i) 
ACMG: very strong - PVS1 - - PVS1 
ACMG: strong PS2, PS3 PS2 PS2 PS1, PS2 PS2 
ACMG: moderate PM2 PM2 PM2 PM2, PM5 PM1, PM2 
ACMG: supporting PP3 - PP3, PP4 - - 
 
Table 2. “uŵŵary of the patieŶts’ features aŶd of the AŵeriĐaŶ College of MediĐal Genetics and Genomics (ACMG) criteria satisfying the 
pathogenic nature of the identified variants in NALCN, MAGEL2 and SCN2A. 
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